Complex N-glycan breakdown by human gut *Bacteroides* involves an extensive enzymatic apparatus encoded by multiple co-regulated genetic loci

Justina Briliūtė¹, Paulina A. Urbanowicz², Ana S. Luis³, Arnaud Baslé¹, Neil Paterson⁴,
Osmond Rebello², Jenifer Hendel², Didier Ndeh¹, Elisabeth C. Lowe¹, Eric C. Martens³,
Daniel I. R. Spencer², David N. Bolam^{*1} & Lucy I. Crouch^{*1}

[^]These authors contributed equally

^{*}To whom correspondence should, be addressed: david.bolam@ncl.ac.uk or
lucy.crouch@ncl.ac.uk.

¹Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. ²Ludger Ltd, Culham Science Centre, Oxfordshire, OX14 3EB, UK.

³Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA. ⁴Diamond Light Source, Didcot, Oxfordshire, OX11 0DE, UK.

Glycans are the major carbon sources available to the human colonic microbiota. Numerous N-glycosylated proteins are found in the human gut, from both dietary and host sources, including immunoglobulins such as IgA which are secreted into the intestine at high levels. Here we show that many mutualistic gut *Bacteroides* spp. have the capacity to utilise complex N-glycans (CNGs) as nutrients, including those from immunoglobulins. Detailed mechanistic studies using transcriptomic, biochemical, structural and genetic techniques reveal the pathway employed by *B. thetaiotaomicron* (*Bt*) for CNG degradation. The breakdown process involves an extensive enzymatic apparatus encoded by multiple non-adjacent loci and comprises 19 different carbohydrate-active enzymes (CAZymes) from different families, including a CNG specific endo-glycosidase activity. Furthermore, CNG degradation involves the activity of CAZymes that have previously been implicated in the degradation of other

classes of glycan. This complex and diverse apparatus provides *Bt* with the capacity to access the myriad different structural variants of CNGs likely to be found in the intestinal niche.

Introduction

The composition of the human gut microbiota is closely associated with many aspects of health, development and disease¹⁻⁴. The major nutrients available to the colonic microbiota are complex carbohydrates and glycan preferences shape the composition of this microbial community⁵. While dietary plant polysaccharides likely make up the bulk of glycans reaching the large intestine, host glycans are also significant nutrient source and access to these host molecules appears to be important for gut colonisation and survival⁶⁻⁹.

N-linked glycans are commonly present within the gut as almost all secreted eukaryotic proteins are N-glycosylated to some extent. N-glycans are composed of a conserved pentasaccharide core capped with a diverse range of different monosaccharides to give three main types; complex, high mannose and hybrid, although there is significant heterogeneity within these structures (Fig. 1a)¹⁰. N-glycans found in the gut come from a range of sources, including dietary animal products and host molecules such as mucins and antibodies^{11,12}. For example, secretory IgA, the major immunoglobulin produced in the intestine, is heavily decorated with mainly CNG structures^{13,14}.

Despite the prominence of N-glycans in the human intestine, there are only a few studies describing their use as nutrients by the microbiota and the pathways of N-glycan breakdown employed by mutualistic microbes. Some strains of *Bifidobacteria* have been found to utilise N-glycans on lactoferrin from milk¹⁵, while *Bt* has been shown to express a single PUL to access high mannose N-glycans (HMNG)⁸. While there is a paucity of data on N-glycan use by the normal gut microbiota, especially of the complex type, these molecules are well known to be key nutrients for some pathogens, as the ability to access N-glycans facilitates survival of these microbes within the extra-intestinal niche¹⁶⁻²¹. Although several studies

describe aspects of N-glycan degradation by enteric pathogens, most of these focus on only a single part of the degradation pathway or the role of this process in virulence²¹⁻²⁴. *Bacteroides* are one of the dominant genera of the human gut²⁵ and are prominent glycan degraders, with many species encoding hundreds of different CAZymes to facilitate access to the diverse array of glycans available^{6-8,26-32}. In *Bacteroides*, the genes encoding the glycan degrading apparatus are usually co-localised in discrete clusters known as polysaccharide utilisation loci (PULs)³³. PULs are typically defined by their composition as containing SusC-like and SusD-like gene pairs that encode the outer membrane glycan import machinery³⁴, as well as a sensor-regulator and multiple CAZymes. Often a single PUL encodes all of the apparatus required to access a specific glycan structure, although multiple PULs have been shown to be involved in the degradation of some highly complex glycans^{5, 35}.

In this study we set out to further our understanding of CNG breakdown by the normal gut microbiota, focusing on prominent *Bacteroides* spp. The data reveal that the ability to utilise CNGs is commonplace amongst gut *Bacteroides* and that growth of *Bt* on CNG activates an extensive enzymatic apparatus encoded by multiple loci, including a single core PUL that likely controls expression of the other non-adjacent loci. Detailed characterisation of the *Bt* CNG breakdown pathway provides significant insights into the mechanism of N-glycan degradation by key members of the microbiota and provides knowledge for future studies examining the role of this process in gut survival.

Results

Growth of gut *Bacteroides* on CNGs

Prominent gut *Bacteroides* spp. were tested for their ability to grow on native Bovine α_1 acid glycoprotein (α_1 AGp) as the sole carbon source (Fig. 1a). Of the 9 species tested, most could grow to some extent on α_1 AGp, with only *B. caccae* and *B. celluloslyticus* showing no growth over 48h (Fig. 1b). Analysis of supernatant after growths revealed that no protein degradation had occurred and protein remaining was almost completely deglycosylated,

indicating that growth was supported by the glycan component of α_1 AGp alone (Supplementary Fig. 1a&b). Growth on other types of CNG-containing glycoproteins was also assessed (Supplementary Fig. 1f) and described in Supplementary Results and Discussion.

RNAseq to identify CNG degrading apparatus

RNAseq was used to identify the predicted CAZyme and associated genes upregulated during growth of *Bt* on α_1 AGp. Six discrete loci were identified from this analysis that were composed of in total 19 predicted CAZymes, 4 SusC/D pairs, and several ORFs of unknown function (Fig. 2, Supplementary Table 1&2, Supplementary Results and Discussion, Supplementary Fig. 2). Only two of the loci are classed as PULs in that they encode predicted CAZymes, SusC/D homologues and sensor-regulators³³. These data indicate that breakdown of CNGs by *Bt* requires the cooperative action of a complex multi-locus encoded machinery. To understand the degradative pathway for CNGs in *Bt* we carried out biochemical characterisation of the CAZymes upregulated on α_1 AGp.

BT0455^{GH33} sialidase is required for growth on CNGs and is localised both on the cell surface and inside the cell.

Mammalian CNGs are often capped with sialic acid (SA), with N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) being the dominant forms, however only Neu5Ac is found in humans (Fig. 1)³⁶. Neu5Gc would therefore only be available to the microbiota from eukaryotic dietary sources, while Neu5Ac would be present in both dietary and host glycans. BT0455^{GH33} is the only sialidase encoded by the *Bt* genome and has been previously characterised as having broad specificity, acting on a range of SA capped structures including CNGs³⁷.

Bt cannot metabolise SA, but requires its removal to enable access to underlying glycan³⁸ and as expected SA build-up can be seen in the supernatant over the course of growth of *Bt* on α_1 AGp (Fig. 1e and Supplementary Fig. 1&3). BT0455^{GH33} was found to be critical for the

112 utilisation of CNGs by *Bt* as a BT0455 deletion strain (Δ BT0455) was unable to grow and the
113 defect could be rescued by addition of recombinant BT0455 to the media (Supplementary
114 Fig. 1).

115 We next examined the cellular location BT0455^{GH33} using a whole cell activity assays and
116 protease protection assays (Supplementary Fig. 4-7 and Supplementary Results and
117 Discussion). Unexpectedly, the data revealed that BT0455^{GH33} is localised both inside the
118 cell and on the cell surface. In the same locus as BT0455^{GH33} is an ORF (BT0457) which
119 shares 70% identity with the *Tannerella forsythia* SA esterase, NanS³⁹. BT0457 was shown
120 to have similar activity to NanS against differentially acetylated forms of SA (Supplementary
121 Fig. 8) and is predicted to be periplasmic, providing a likely explanation for the unusual dual
122 surface and periplasmic localisation of the sialidase BT0455^{GH33}. This is discussed in more
123 detail in Supplementary Results and Discussion.

125 **CNGs are cleaved from native glycoproteins at the cell surface by GH18 endo-** 126 **glucosaminidases.**

127 Previously characterised members of the GH18 family include endo- β -N-
128 acetylglucosaminidases with a range of different specificities against different types of N-
129 glycans (Supplementary Table 3). The RNAseq data revealed four GH18 family members
130 upregulated during growth on α_1 AGp (Fig. 2), which were tested for activity against a variety
131 of N-glycosylated proteins including those with different CNG, high mannose, plant-type and
132 hybrid structures (Supplementary Fig. 9a&b). Surprisingly, only BT1044^{GH18} displayed
133 activity against any of the glycoproteins tested, and of the substrates tested this was limited
134 to release of glycans from α_1 AGp, IgA and IgG from human serum, and IgA from human
135 colostrum (IgA^s, IgG^s and IgA^c, respectively). None of the four GH18 family members were
136 active on chitin or chito-oligosaccharides (Supplementary Fig. 9c).

137 To investigate the specificity of BT1044^{GH18} in more detail, products from digested
138 glycoproteins were labelled with the fluorophore procainamide and analysed by liquid
139 chromatography-fluorescence detection-electrospray-mass spectrometry (LC-FLR-ESI-MS)

(Fig. 3a&b, Fig. 4a-c). The structures of the various CNGs were determined using MS/MS and showed predominantly bi-antennary CNG structures released, including species with bisecting GlcNAcs, antenna fucosylation and polyLacNAc antenna structures. Tri-antennary N-glycan can also be removed, but only if the third antenna is limited to a single GlcNAc (e.g. Fig. 4, *glycan 5*). In comparison, PNGaseF treatment (removes all N-glycan structures) revealed tri-antennary CNG structures were present on IgA^s and bovine fetuin, but these were not removed by BT1044^{GH18} (Supplementary Fig. 10 & 11a-c).

Assays against sialylated and desialylated forms of α_1 AGp with BT1044^{GH18} showed the enzyme can act on both, but with a preference for the latter, suggesting removal of CNGs from the protein mainly occurs after the action of the surface sialidase (Supplementary Fig. 9d). The GH18 EndoE from *Enterococcus faecalis* also has a preference for desialylated N-glycans ⁴⁰, whereas the GH18 EndoS₂ from *Streptococcus pyogenes* can remove either type without preference ²² (Supplementary Table 3). BT1044^{GH18} was also shown to tolerate fucosylation of the core GlcNAc (Supplementary Fig. 12a).

A Δ BT1044 strain displayed only a minor growth defect on α_1 AGp compared to the wild type strain (Supplementary Fig. 1g). Furthermore, analysis of surface enzyme activity of Δ BT1044 vs wild type cells against α_1 AGp showed similar product profiles (Supplementary Fig. 7a) and treatment of α_1 AGp using both BT0455^{GH33} and BT1044^{GH18} revealed the level of deglycosylation appeared less than after growth on this glycoprotein (Supplementary Fig. 1a&c). Together, these data suggest that in addition to BT1044^{GH18}, one or more of the other three upregulated GH18 members or a currently unknown enzyme, are also involved in deglycosylating CNGs *in vivo*. This apparent redundancy in GH18 activity has been observed previously in *Bacteroides* spp; a *B. fragilis* mutant strain lacking the main GH18 upregulated during growth on rat transferrin retained the ability to grow on the serum glycoprotein, albeit at a slower rate²⁰. Deletion of the other three *Bt* GH18 genes upregulated on CNGs was attempted to explore their role further, but we were unable to obtain these mutants.

The structure of BT1044^{GH18} endo-glucosaminidase

To investigate the structural basis for substrate specificity displayed by BT1044^{GH18}, the crystal structure of the enzyme was solved to 2.4 Å resolution (Fig. 4). BT1044^{GH18} adopts the canonical (β/α)₈ barrel (TIM barrel) fold common to many GH structures. Notably, the N-terminal region forms a discrete extended structure that would orientate the lipoprotein on the cell surface with the active site facing the extracellular environment (Fig. 4d & Supplementary Results and Discussion). This is likely necessary to prevent spatial restrictions in accessing bulky native glycoprotein substrates. Furthermore, there are ~20 amino acids after the N-terminal lipid anchoring Cys that are not visible in the structure. It appears likely therefore that this region acts as a relatively unstructured linker between the lipid anchor and the folded N-terminal domain to further extend the distance between the cell surface and the enzyme's active site. To understand substrate specificity in more detail, the structure of BT1044^{GH18} was compared to that of *Elizabethkingia meningoseptica* GH18 (EndoF3) in complex with a biantennary CNG product (Fig. 4e & see Supplementary Results and Discussion)⁴¹.

CNG structures are predominantly degalactosylated in the periplasm by BT0461^{GH2}

SA removal from CNGs exposes the predominantly β1,4-linked galactose (although occasionally this can be β1,3-linked) (Fig. 1)⁴². Inspection of the CAZymes upregulated on α1AGp revealed only two possible β-galactosidase candidates; BT0458^{GH2} and BT0461^{GH2}. As BT0458 has previously been shown to be a β-mannosidase⁴³, BT0461^{GH2} alone was screened against a variety of defined β-galactose substrates and found to have a preference for the structures and linkages found in CNGs (Supplementary Table 4). BT0461^{GH2} was tested on BT1044^{GH18}-liberated CNG from α1AGp pre-treated with BT0455^{GH33} and the products were predominantly fully degalactosylated (Fig. 3c). PNGaseF-liberated and desialylated CNG from IgA^s, IgG^s and IgA^c substrates were also tested. All of the galactose was removed from the IgG^s and IgA^s glycans, but there was a minor population of galactose-containing structures remaining from the IgA^c sample

(Supplementary Fig. 11d-f). The IgA^c glycans with antenna fucosylation on the +1 sugar (GlcNAc) were not degalactosylated, indicating the fucose was blocking access of BT0461^{GH2}. A lack of BT0461^{GH2} activity against fucosylated LacNAc and LNB (Lewis X and A, respectively) supported the need for antennary fucose removal prior to galactose release (Fig. 1, Supplementary Fig. 11k & Supplementary Results and Discussion). The antennary fucose, which often decorates CNG structures, is removed by BT1625^{GH29} fucosidase (Supplementary Fig. 11d and Supplementary Table 7). Details of BT1625^{GH29} activity are described in Supplementary Results and Discussion.

The multiple GH20 genes upregulated on α_1 AGp display complementary but overlapping activities against CNG

Degalactosylation of CNGs reveals β -linked GlcNAcs which are β 1,2 linked in biantennary, but β 1,4 (on the α 1,3 arm) and β 1,6 (on α 1,6 arm) in tri- and tetra-antennary CNG, respectively (Fig. 1). The core mannose can also have a β 1,4 GlcNAc (termed 'bisecting'). GH20 family members are known to be predominantly exo-acting β -hexosaminidases and four of these were expressed during growth on α_1 AGp (Fig. 2). Localisation studies indicate all were most likely periplasmic (Supplementary Fig. 7c). Notably, two of the enzymes contain a Type II signal sequence suggesting they are membrane associated but are not trafficked to the cell surface (Supplementary Table 2).

To define the specificity of the four GH20 enzymes they were tested against CNGs from α_1 AGp, IgG^s, IgA^s and IgA^c liberated with PNGaseF and pre-treated with BT0455^{GH33} and BT0461^{GH2} (Fig. 5 and Supplementary Table 6 & Supplementary Fig. 11e-g). Activity of the GH20 family members was also tested against CNGs released by PNGase from IgG^s with no pre-treatment with BT0455^{GH33} and BT0461^{GH2} (Supplementary Fig. 13).

BT0506^{GH20} is specific and highly active against the antenna GlcNAcs, but failed to have any activity against the bisecting β 1,4-GlcNAc. BT0459^{GH20} is also predominantly specific for a range of antenna GlcNAcs, however, trace activity on bisecting structures could be detected. The difference between these enzymes is BT0459^{GH20} struggles to remove both antenna

GlcNAcs, usually when a bisecting GlcNAc is present, indicative of a steric block (Supplementary Fig 11 e.g. *glycans* 28 & 31).

In contrast, BT0456^{GH20} and BT0460^{GH20} were both able to remove the bisecting GlcNAc when samples had SA and Gal removed. Any further antenna decoration meant BT0456^{GH20} was no longer active on bisecting structures. BT0460^{GH20}, however, could remove bisecting GlcNAc even when both antennae had Gal and SA present (Supplementary Fig. 13 & Supplementary Table 6).

In terms of antennary deglycosylation, BT0460^{GH20} was able to remove all GlcNAc in the substrates tested, while products from the BT0456^{GH20} had a high proportion with only one uncapped GlcNAc remaining indicating a preference for one arm. Furthermore, if the one antenna has a Gal (or SA as well) cap, then BT0456^{GH20} cannot not access the GlcNAc on the other antenna, again indicating a preference for one arm or a steric block (Supplementary Fig. 13, *glycans* 4, 6 and 11 remaining). Overall these data reveal that the four the *Bt* GH20 family members characterised here display complementary but overlapping activities that facilitate access to the diverse GlcNAc linkages present on CNGs.

Crystal structure of BT0459^{GH20} GlcNAc'ase

The structure of BT0459^{GH20} was solved to 2.4 Å with GlcNAc product present in the -1 subsite. The enzyme is made up of four domains – a small N-terminal domain, a (β/α)₈ barrel catalytic domain, an FN3 domain and a C-terminal F5/F8 type C domain that are oriented overall to form a hook-like shape with the C-terminal domain facing the active site (Fig. 6). The potential role of the C-terminal F5/F8 type C domain in substrate binding is discussed in Supplementary Results and Discussion.

Compared to other known GH20 structures, BT0459^{GH20} has a very open active site structure with only the -1 site, indicating little interaction with the +1 sugar and potentially providing a rationale for the broad substrate specificity displayed by this enzyme (Fig. 6a&b and Supplementary Fig. 14-16). A comparison of this active site with CNG-active *Sp*GH20A and *Sp*GH20B from *S. pneumoniae* (Fig. 6c&d)⁴⁴ and also a GH20 from *Ostrinia furnacalis*

(Fig. 6e) specific for chitooligosaccharides⁴⁵ highlights the unusual openness of the BT0459^{GH20} active site (Supplementary Results and Discussion).

BT1035^{GH163} is a surface located enzyme with CNG-specific endo GlcNAc'ase activity

Within the large CNG-upregulated locus is an ORF (BT1035) of unknown function that sequence analysis suggests is a glycoside hydrolase. It is predicted to have an N-terminal DUF4838 domain that has distant homology to GH20 and a C-terminal F5/F8 type C domain. Incubation of recombinant BT1035^{GH163} against BT1044^{GH18}-liberated CNG from α_1 AGp showed it was able to release sialylated LacNAc (both Neu5Ac and Neu5Gc) (Fig. 3a&d). BT1035^{GH163} was able to act on the CNG while still attached to the protein, but displayed a preference for the GH18 released glycan (Supplementary Fig. 17c). The enzyme was also capable hydrolysing the same GlcNAc- β 1,2-Mannose linkage in desialylated α_1 AGp (Fig. 3b&e). Comparison of BT1035^{GH163} activity against sialylated and desialylated CNGs showed that desialylated CNG was found to be a more favourable substrate, possibly indicating that SA attached through particular linkages cannot be accommodated by the enzyme (Supplementary Fig. 18). CNG structures with SA linked to the GlcNAc were not hydrolysed by BT1035^{GH163}, indicating the enzyme has no -1' subsite (Fig. 3d, no SA-GlcNAc products). BT1035^{GH163} was also able to remove larger diLacNAc structures from CNG antenna, however the enzyme could not degrade the diLacNAc product further, suggesting that either the +1 subsite cannot tolerate Gal, or has a requirement for Man i.e. is CNG specific, or the enzyme is linkage-specific (Fig. 3b&e).

Using CNGs pre-treated with BT0455^{GH33} and BT0461^{GH2} revealed BT1035^{GH163} was also able to hydrolyse the GlcNAc- β 1,2-Mannose linkage to almost totally remove both the remaining GlcNAc and LacNAc, showing that the galactose in the -2 subsite is not an absolute requirement for activity (Fig. 3c&f). Notably, however, BT1035^{GH163} was unable to cleave the GlcNAc- β 1,2-Mannose disaccharide (Supplementary Fig. 17a), indicating interactions with a +2 subsite are required for activity (i.e. with the core mannose), although the context of this sugar would vary depending on the specific arm targeted. Activity against

IgA and IgG showed that bisecting GlcNAc does not interfere with BT1035^{GH163} hydrolysis (Supplementary Fig. 11h-j).

The capacity of to remove LacNAc, sialyl LacNAc and diLacNAc from CNGs and lack of activity against the GlcNAc-Man disaccharide indicate BT1035^{GH163} displays an endo-like activity that targets the β -GlcNAc-Man found in these structures.

Analysis of the cellular location of BT1035^{GH163} revealed the enzyme is on the cell surface, providing an explanation for the release of a sialylated-LacNAc structure (predominantly Neu5Gc) outside the cell during growth on α_1 AGp (Supplementary Figs. 1, 3 & 4). Growth data suggest that BT0455^{GH33} and BT1035^{GH163} are both active *in vivo* from early to mid-exponential onwards, with SA released slightly earlier (Supplementary Fig. 1). Whole cell assay data also show BT0455^{GH33} and BT1035^{GH163} both act rapidly on α_1 AGp *in vitro*, but the sialylated-LacNAc structures produced by BT1035^{GH163} remain sialylated. This suggests that BT1035^{GH163} is accessing glycan structures that BT0455^{GH33} cannot *in vivo* and a biological rationale for this activity on the cell surface of BT1035^{GH163} may be to increase the proportion of CNG structures that can be accessed.

It may also be that CNGs with particular structures are poor substrates for the SusCD glycan import apparatus and thus removal of some trisaccharides by BT1035^{GH163} facilitates more efficient uptake of these glycans (see Supplementary Results and Discussion).

Discussion

This study characterises the pathway for CNG breakdown by a prominent member of the normal human gut microbiota. CNGs are highly variable in terms of sugar composition and linkages, displaying extensive heterogeneity even within a single glycoprotein⁴⁶. For

example, human IgG is decorated with 18 different N-glycan structures, few of which are shared with the other glycoproteins tested here.

Here we describe the extensive enzyme apparatus *Bt* uses to deal with this heterogeneity. We show that significant processing of predominantly biantennary forms of CNG occurs at the cell surface prior to import, including removal of glycan from the protein, desialylation and the action of BT1035^{GH163}. The exact biological advantage BT1035^{GH163} provides could not be fully elucidated in this study, but one role may be to increase the variety of CNGs that *Bt* can access. After removal of galactose and antennary fucose, the complementary but overlapping activities of the four different GH20 enzymes allow access to a diverse range of antennary and bisecting GlcNAc structures.

Notably, the broad specificity of the exo-acting enzymes could be a reflection of their role in the degradation of multiple types of glycan with conserved structural features in common. Thus, many of the enzymes involved in CNG breakdown in *Bt* also appear to play a role in the degradation of O-glycans; both the BT0455-BT0461 locus and BT1624-BT1625 have been shown to be expressed during growth of *Bt* on mucin^{26,47}. It is possible that the shared structures contained within O-glycans and CNGs (i.e. β -linked Gal and GlcNAcs, as well as capping SA and fucose) targeted by these enzymes and the consistent presence of these glycans from host sources in the gut (i.e. less variable than dietary glycans) have driven the overlapping regulation of these enzymes in *Bt*.

Related to this, a previous study indicates that the anti-sigma regulator of the core BT1032-BT1053 CNG PUL, BT1053, directly controls expression of the whole multi-locus CNG degradation apparatus⁴⁸. Thus, when BT1053 was deleted to derepress the genes under its

control, the same loci were upregulated as were seen here to be activated by CNGs. As the sensor-regulator for the core BT1032-BT1053 PUL is an ECF-sigma/anti-sigma system, the activating signal for expression of the whole *Bt* multi-locus CNG apparatus will be import of discrete CNG structures by the core PUL encoded SusCD.

The ability of *Bacteroides* spp. to deglycosylate secretory IgA is an interesting finding of this work which raises the possibility that this process plays a role in modulating the function of this important gut immune molecule and is an intriguing avenue of research to pursue in the future^{11,49,50}.

Methods

Sources of glycans and glycoproteins. Glycoproteins bovin α_1 acid glycoprotein, bovine fetuin, bovine RNaseB, chicken egg white ovalbumin, horseradish peroxidase, human serum IgG, human serum IgA, human colostrum IgA and *p*-Nitrophenyl (PNP) monosaccharides were obtained from Sigma. Purified di- and oligo-saccharides were obtained from Carbosynth. The sialic acid reference panel was obtained from Ludger. Squid chitin was a gift from Prof. Gideon Davies (Univ. of York, UK).

Bacterial strains. *Bacteroides* strains used were as follows: *B. thetaiotaomicron* VPI-5482, *B. fragilis* NCTC9342, *B. caccae* ATCC43185, *B. cellulosilyticus* DSM14838, *B. massiliensis* DSM17679, *B. fingoldii* DSM17565, *B. vulgatus* ATCC8483, *B. ovatus* ATCC8482 and *B. xylanisolvens* XBA1.

Cloning, expression and purification of recombinant proteins. DNA encoding the appropriate genes (excluding the signal sequences) were amplified from genomic DNA using appropriate primers and cloned into pET28b (Novagen) using NheI-XhoI restriction sites. His-tags were located at the N-terminus. Recombinant plasmids were transformed into TUNER (Novagen) cells in LB broth containing 10 μ g/ml kanamycin at 37 °C shaking at 180

rpm. One litre cultures were grown to mid-exponential phase in 2 litre baffled flasks, cooled to 16 °C and isopropyl β -D-thiogalactopyranoside (IPTG) added to a final concentration of 0.2 mM. These cells were then incubated for 16 hours at 16 °C in an orbital shaker at 150 rpm. Recombinant His-tagged protein was purified from cell-free extracts using immobilised metal affinity chromatography (IMAC using Talon resin; Clontech) as described previously⁵¹. The purity and size of the proteins were checked using SDS-PAGE and their concentrations determined using absorbance at 280 nm (NanoDrop 2000c; Thermo Scientific) and their molar extinction coefficients⁵².

Purification of proteins for crystallisation. IMAC-purified proteins were further purified by SEC using a HiLoad™ Superdex 200 pg on an AKTA Pure FPLC system (GE Healthcare Life Sciences). The purity of the fractions were determined using SDS-PAGE and those of high enough purity were pooled and concentrated to ~ 10 mg/ml.

Crystallisation.

We used the vapour diffusion sitting drop method to screen crystallisation conditions.

Seleno-methionine (SeMet) crystals for BT1044^{GH18} were obtained in 100 mM imidazole pH 8.0 and 10 % polyethylene glycol (PEG) 8000. The sample were cryo-protected with paratone-N oil. Additional SeMet BT1044^{GH18} crystals were obtained in 200 mM sodium fluoride, 100 mM bis-tris propane pH 6.5 and 20 % PEG 3350. These samples were cryo-protected with the addition of 20% PEG 400 to the reservoir solution. BT0459^{GH20} crystals were obtained in 100 mM sodium acetate, 100 mM bis-tris propane pH 7.5 and 10 % PEG3350.

Data collection, structure solution, model building, refinement and validation.

A 3-wavelength interleaved MAD experiment using SeMet derivatives cryo-protected with oil was collected at the beamline I03, Diamond Light Source (UK). The data were indexed and integrated with XDS⁵³. Space group determination was confirmed with Pointless and the data were scaled with Aimless⁵⁴. The phase problem for BT1044^{GH18} was solved by autoSHARP⁵⁵. ShelxD⁵⁶ found the requested 8 selenium sites with a final correlation coefficient (E) of 0.59. Subsequent density modification with Parrot⁵⁷ and automated model

building with Buccaneer⁵⁸ placed 292 sequenced residues out of 364. Once the phase problem was solved, higher resolution datasets were obtained on the BT1044^{GH18} SeMet samples cryo-protected with PEG 400 (see above). The data were processed as above and the initial experimental phasing model was refined using Refmac5⁵⁹ and manually built using Coot⁶⁰. The data processing and refinement statistics are reported in **Supplementary Table 8; PDB accession 6Q64**. The phase problem for BT0459^{GH20} was solved by using MrBump⁶¹. Briefly, the search model 3RCN was prep with Molrep⁶² and used in Phaser⁶³ all automated through MrBump⁶¹. The initial phases obtained from MrBump were improved by density modification using Parrot⁵⁷ and the model was automatically build using Buccaneer⁵⁸. For all models, iterative cycles of model building with Coot⁶⁰ and refinement with Refmac5⁵⁹ were stopped when the validation with Coot⁶⁰ and Molprobability⁶⁴ gave acceptable values. 5 % of the data were randomly selected for Rfree calculation. Structural figures were made using Pymol⁶⁵ and all other programs used were from the CCP4 suite⁶⁶. The data processing and refinement statistics are reported in **Supplementary Table 8; PDB accession 6Q63**.

Growth of *Bacteroides* species. Starter cultures for most *Bacteroides* spp. were grown in tryptone-yeast-extract-glucose (TYG) medium with the addition of hematin and inoculated from glycerol stocks³². *Bacteroides massiliensis* and *xylanisolvens* were grown on chopped meat broth (CMB) as described previously^{9,67}. Cells were typically grown in 5 ml cultures in glass test tubes in an anaerobic cabinet (Whitley A35 Workstation; Don Whitley, UK) and were monitored at OD_{600nm} using a Biochrom WPA cell density meter. Growth tests using 20 mg/ml glycoprotein as the sole carbon source were carried out in minimal media (MM)³³ in either 5 ml cultures (to allow for taking samples) or 600 µl cultures in a 96 well plate using a Biotek Epoch plate reader. The removal of glycan from peptide was monitored by SDS-PAGE with either Coomassie staining or Pierce™ Glycoprotein staining kit (ThermoFisher Scientific), to detect just protein or glycoprotein, respectively. Replicates are presented individually in the figures and not as averages.

RNA extraction, sequencing and data processing. A starter culture was used to inoculate minimal media (5 ml) of either 5 mg/ml glucose or 10 mg/ml α_1 AGp, which was then grown to OD_{580nm} 0.4-0.6. Cells were harvested and stored in RNAProtect (QIAGEN) and the RNA extracted using RNeasy Mini Kit (Qiagen). Sample processing, library prep and sequencing took place at Oxford Genomics Centre (University of Oxford, Oxford, UK). Data processing was done by The Bioinformatics Support Unit at Newcastle University using Bowtie2 for alignments⁶⁸ and genome annotation completed using the Ensembl database⁶⁹. The read counts aligning to the genomic features were obtained and differential expression analysis was done using R packages⁷⁰. This data is presented in **Supplementary Table 1** has been submitted to <https://www.ncbi.nlm.nih.gov/geo/> and has the **accession number GSE129572**.

Genetic manipulation. Gene deletion mutations were produced by allelic exchange using the pExchange vector⁶.

Cellular localisation. Cells (15 ml) were grown on minimal media with α_1 AGp (10 mg/ml final) to mid-exponential growth, harvested by centrifugation, washed in PBS and resuspended in 2 ml PBS. The cells were split into two. One half had Proteinase K (2 mg/ml final) added and was incubated at 37 °C for 2 hours and one half was the control. The Proteinase K sample was harvested by centrifugation, washed in PBS and resuspended in 1 ml. Trichloroacetic acid (200 μ l) was added to all samples to precipitate out the protein, incubated for 30 mins on ice, washed four times with ice-cold acetone (1ml) and cell pellets resuspended in 0.5 ml PBS. Samples (15 μ l) were run on SDS-PAGE gels with MagicMark XP Western Protein Standard (Thermo Fisher Scientific) and then transferred to Whatman Protran BA 85 nitrocellulose membrane. Specific proteins were detected using anti-sera raised against recombinant versions in rabbit (Eurogentec). The secondary antibody used was a Goat Anti-rabbit HRP conjugate (SC-2004, Santa Cruz). Antibodies were detected by chemi-luminescence using Biorad Clarity Western ECL Substrate.

Whole cell assays to analyse cell surface enzyme activity. 15 ml cultures grown on minimal media with α_1 AGp (20 mg/ml final) to mid-exponential and harvested by

centrifugation. Cells were washed twice in PBS and resuspended in 1.75 ml PBS. To assess the cell surface activity, 250 μ l of the resuspended cells were mixed with 250 μ l of fresh α_1 AGp added (20 mg/ml final) and a 50 μ l aliquot was taken at T=0, 0.25, 0.5, 1, 2, 3, 4 and ~16 h. One aliquot was pelleted again and resuspended in 250 μ l of BugBuster® (Merck Millipore) to lyse the cells and then mixed with 250 μ l of fresh α_1 AGp (20 mg/ml final). Several controls were also included. Cells (250 μ l) were mixed with 250 μ l PBS, 250 μ l of the spent media from the growth was also mixed with 250 μ l of fresh α_1 AGp (20 mg/ml final) and 500 μ l of cells were mixed with 500 μ l of PBS. For the latter control, two 50 μ l aliquots were taken at every time point and one was checked for activity and one had the cells were removed by centrifugation and the supernatant kept on ice. The supernatant was tested for overnight activity against fresh α_1 AGp (20 mg/ml final) to check there was no cell lysis during the time course. Cells (750 μ l) were then treated with Proteinase K (2 mg/ml final) for two hours and again harvested by centrifugation, washed twice and resuspended back to 750 μ l. 250 μ l of these cells were mixed with α_1 AGp (20 mg/ml final) and the same time course run. To check all the Proteinase K had been removed, 250 μ l of the treated cells were mixed with 250 μ l of bovine serum albumin (20 mg/ml final). The treated cells were also lysed using BugBuster® and assayed against α_1 AGp (20 mg/ml final).

Thin layer chromatography. Between 3-12 μ l of samples were spotted in 3 μ l aliquots on to silica plates and resolved in butanol:acetic acid:water (2:1:1). Sugars were visualised using diphenylamine-aniline-phosphoric acid stain⁷¹.

Recombinant enzyme assays. Generation of kinetic data was carried out with either assays on PNP-linked sugars (monitored at 400 nm) or using galactose, mannose or fucose detection kits (Megazyme International), as described previously⁸. To assay the activity of enzymes on CNG, reactions were left overnight (~16h) unless otherwise stated. The activities of the recombinant enzymes were typically assessed in 20 mM MOPS pH 7, at 37 °C, with a final glycoprotein concentration of 20 mg/ml and a final enzyme concentration of 1 μ M. Exceptions to this were the final concentrations of IgG, serum IgA and colostrum IgA that were 5 mg/ml, 0.5 mg/ml and 2.5 mg/ml, respectively. All kinetic assays were performed

at least in triplicate on multiple occasions and data presented are means and standard deviations. Total N-glycans were released from glycoproteins using PNGaseF (sigma), purified by centrifugation through a 10 kDa protein concentrator, freeze dried and resuspended in the required volume.

Esterase activity. A sialic acid reference panel containing differently esterified sialic acid species was digested with 1 μ M of BT0457 overnight at 37 °C, derivatised with DMB (Ludger, Ltd) and analysed using reversed phase HPLC. Here, 25 μ l of sample was injected into the LudgerSep R1 column (4.6 x 150 mm, 3 μ m particle size) at 30 °C on a Waters Alliance HPLC instrument with fluorescence detection (λ_{ex} = 373 nm, λ_{em} = 448 nm). Mobile phase A was a methanol: acetonitrile: water solution (7:9:84) and mobile phase B was acetonitrile. Analytes were eluted using an isocratic flow at 100 % mobile phase A running at a flow rate of 0.5 mL/min for 19 minutes. Column wash was accomplished by increasing proportion of mobile phase B to 90 %.

High-performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD). HPAEC-PAD was used to analyse BT1035^{GH163} activity against sialylated and desialylated CNGs. Samples were separated using a CARBOPAC™ PA-100 anion exchange column with a CARBOPAC™ PA-100 guard column (Thermo Fisher Scientific). Flow was 1 ml/min and elution conditions were 0-20 min, 20 mM NaOH; 20-80 min 100 mM NaOH with a 0-500 mM sodium acetate gradient. LacNAc was quantified using a standard curve generated using a range of LacNAc standards between 0.1 and 0.01 μ M.

Procinamide labelling. N-glycans were fluorescently labelled by reductive amination using a procinamide labelling kit containing sodium cyanoborohydride as reductant (Ludger, Ltd). Before analysis, derivative glycans were cleaned-up from excess reagents using SPE clean-up plates (Ludger, Ltd).

Analysis of Procinamide labelled glycans. Procinamide labelled glycans were analysed by LC-FLR-ESI-MS. Here, 25 μ l of each sample was injected into a Waters ACQUITY UPLC Glycan BEH Amide column (2.1 x 150 mm, 1.7 μ m particle size, 130 Å pore size) at 40°C on a Dionex Ultimate 3000 UHPLC instrument with a fluorescence detector (λ_{ex} = 310 nm, λ_{em} =

370 nm) attached to a Bruker Amazon Speed ETD. Mobile phase A was a 50 mM ammonium formate solution (pH 4.4) and mobile phase B was neat acetonitrile. Analyte separation was accomplished by a gradient running from 85-57% mobile phase B over 105 minutes at a flow rate of 0.4 mL/min, with exception of IgG CNG used for screening of GH20 enzymes, where separation was accomplished by a gradient running from 76-58% mobile phase B over 70 minutes. The Amazon Speed was operated in the positive sensitivity mode using following settings: source temperature, 180 C; gas flow, 4 L/min; capillary voltage, 4500 V; ICC target, 200,000; maximum accumulation time, 50.00 ms; rolling average, 2; number of precursor ions selected, 3; scan mode, enhanced resolution; mass range scanned, 400 to 1700.

Analysis of mass spectrometry data. Procainamide labelled glycans were analysed using Bruker Compass Data Analysis software and GlycoWorkbench⁷². Glycan compositions were elucidated based on MS² fragmentation and literature knowledge.

Bioinformatics. Putative signal sequences were identified using LipoP⁷³. Alignments and sequence identities were determined using Clustal Omega using the full length protein sequences, not individual modules⁷⁴. The IMG database was used to analyse genomic locations and synteny⁷⁵. The CAZy database (www.cazy.org) was used as the main reference for carbohydrate-active enzyme activity⁷⁶. Dali⁷⁷ and PDBefold⁷⁸ were used to carry out structural homology searches of protein modules. Phylogenetic trees were constructed using Phylogeny.fr^{79,80}. Pfam⁸¹ and SMART^{82,83} were used to determine module boundaries and look at the prevalence of modules in other proteins.

Data availability. The full RNAseq data is provided in Supplementary Table 1 and is also submitted to <https://www.ncbi.nlm.nih.gov/geo/> with the accession number GSE129572. The crystal structures are deposited in the Protein Data Bank under the accession numbers 6Q63 and 6Q64. The other data that support the findings in this paper are available upon request from the corresponding authors.

References

- 1 McNeil, N. I. The contribution of the large intestine to energy supplies in man. *The American journal of clinical nutrition* **39**, 338-342, doi:10.1093/ajcn/39.2.338 (1984).
- 2 Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. *Nature* **444**, 1022-1023, doi:10.1038/4441022a (2006).
- 3 Khoruts, A., Dicksved, J., Jansson, J. K. & Sadowsky, M. J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent *Clostridium difficile*-associated diarrhea. *Journal of clinical gastroenterology* **44**, 354-360, doi:10.1097/MCG.0b013e3181c87e02 (2010).
- 4 O'Keefe, S. J. *et al.* Products of the colonic microbiota mediate the effects of diet on colon cancer risk. *The Journal of nutrition* **139**, 2044-2048, doi:10.3945/jn.109.104380 (2009).
- 5 Koropatkin, N. M., Cameron, E. A. & Martens, E. C. How glycan metabolism shapes the human gut microbiota. *Nature reviews. Microbiology* **10**, 323-335, doi:10.1038/nrmicro2746 (2012).
- 6 Koropatkin, N. M., Martens, E. C., Gordon, J. I. & Smith, T. J. Starch catabolism by a prominent human gut symbiont is directed by the recognition of amylose helices. *Structure (London, England : 1993)* **16**, 1105-1115, doi:10.1016/j.str.2008.03.017 (2008).
- 7 Luis, A. S. *et al.* Dietary pectic glycans are degraded by coordinated enzyme pathways in human colonic *Bacteroides*. *Nature microbiology* **3**, 210-219, doi:10.1038/s41564-017-0079-1 (2018).
- 8 Cuskin, F. *et al.* Human gut *Bacteroidetes* can utilize yeast mannan through a selfish mechanism. *Nature* **517**, 165-169, doi:10.1038/nature13995 (2015).
- 9 Desai, M. S. *et al.* A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* **167**, 1339-1353.e1321, doi:10.1016/j.cell.2016.10.043 (2016).
- 10 Chung, C. Y., Majewska, N. I., Wang, Q., Paul, J. T. & Betenbaugh, M. J. SnapShot: N-Glycosylation Processing Pathways across Kingdoms. *Cell* **171**, 258-258.e251, doi:10.1016/j.cell.2017.09.014 (2017).
- 11 Mathias, A. & Corthesy, B. N-Glycans on secretory component: mediators of the interaction between secretory IgA and gram-positive commensals sustaining intestinal homeostasis. *Gut microbes* **2**, 287-293, doi:10.4161/gmic.2.5.18269 (2011).
- 12 Corfield, A. P. The Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in Human. *Microorganisms* **6**, doi:10.3390/microorganisms6030078 (2018).
- 13 Mestecky, J., Russell, M. W., Jackson, S. & Brown, T. A. The human IgA system: a reassessment. *Clinical immunology and immunopathology* **40**, 105-114 (1986).
- 14 Hughes, G. J., Reason, A. J., Savoy, L., Jaton, J. & Frutiger-Hughes, S. Carbohydrate moieties in human secretory component. *Biochimica et biophysica acta* **1434**, 86-93 (1999).
- 15 Garrido, D. *et al.* Endo-beta-N-acetylglucosaminidases from infant gut-associated bifidobacteria release complex N-glycans from human milk glycoproteins. *Molecular & cellular proteomics : MCP* **11**, 775-785, doi:10.1074/mcp.M112.018119 (2012).
- 16 Sebaihia, M. *et al.* The multidrug-resistant human pathogen *Clostridium difficile* has a highly mobile, mosaic genome. *Nature genetics* **38**, 779-786, doi:10.1038/ng1830 (2006).
- 17 Bohle, L. A., Mathiesen, G., Vaaje-Kolstad, G. & Eijsink, V. G. An endo-beta-N-acetylglucosaminidase from *Enterococcus faecalis* V583 responsible for the hydrolysis of high-mannose and hybrid-type N-linked glycans. *FEMS microbiology letters* **325**, 123-129, doi:10.1111/j.1574-6968.2011.02419.x (2011).
- 18 Renzi, F. *et al.* The N-glycan glycoprotein deglycosylation complex (Gpd) from *Capnocytophaga canimorsus* deglycosylates human IgG. *PLoS pathogens* **7**, e1002118, doi:10.1371/journal.ppat.1002118 (2011).

567 19 Collin, M. & Fischetti, V. A. A novel secreted endoglycosidase from *Enterococcus faecalis*
568 with activity on human immunoglobulin G and ribonuclease B. *The Journal of biological*
569 *chemistry* **279**, 22558-22570, doi:10.1074/jbc.M402156200 (2004).

570 20 Cao, Y., Rocha, E. R. & Smith, C. J. Efficient utilization of complex N-linked glycans is a
571 selective advantage for *Bacteroides fragilis* in extraintestinal infections. *Proceedings of the*
572 *National Academy of Sciences of the United States of America* **111**, 12901-12906,
573 doi:10.1073/pnas.1407344111 (2014).

574 21 Robb, M. *et al.* Molecular Characterization of N-glycan Degradation and Transport in
575 *Streptococcus pneumoniae* and Its Contribution to Virulence. *PLoS pathogens* **13**, e1006090,
576 doi:10.1371/journal.ppat.1006090 (2017).

577 22 Sjogren, J. *et al.* EndoS2 is a unique and conserved enzyme of serotype M49 group A
578 *Streptococcus* that hydrolyses N-linked glycans on IgG and alpha1-acid glycoprotein. *The*
579 *Biochemical journal* **455**, 107-118, doi:10.1042/bj20130126 (2013).

580 23 Collin, M. & Olsen, A. EndoS, a novel secreted protein from *Streptococcus pyogenes* with
581 endoglycosidase activity on human IgG. *The EMBO journal* **20**, 3046-3055,
582 doi:10.1093/emboj/20.12.3046 (2001).

583 24 Dupoirson, S. *et al.* The N-Glycan cluster from *Xanthomonas campestris* pv. *campestris*: a
584 toolbox for sequential plant N-glycan processing. *The Journal of biological chemistry* **290**,
585 6022-6036, doi:10.1074/jbc.M114.624593 (2015).

586 25 Forster, S. C. *et al.* A human gut bacterial genome and culture collection for improved
587 metagenomic analyses. *Nature biotechnology* **37**, 186-192, doi:10.1038/s41587-018-0009-7
588 (2019).

589 26 Martens, E. C. *et al.* Recognition and degradation of plant cell wall polysaccharides by two
590 human gut symbionts. *PLoS biology* **9**, e1001221, doi:10.1371/journal.pbio.1001221 (2011).

591 27 Rogowski, A. *et al.* Glycan complexity dictates microbial resource allocation in the large
592 intestine. *Nature communications* **6**, 7481, doi:10.1038/ncomms8481 (2015).

593 28 Ndeh, D. *et al.* Complex pectin metabolism by gut bacteria reveals novel catalytic functions.
594 *Nature* **544**, 65-70, doi:10.1038/nature21725 (2017).

595 29 Bagenholm, V. *et al.* Galactomannan Catabolism Conferred by a Polysaccharide Utilization
596 Locus of *Bacteroides ovatus*: ENZYME SYNERGY AND CRYSTAL STRUCTURE OF A beta-
597 MANNANASE. *The Journal of biological chemistry* **292**, 229-243,
598 doi:10.1074/jbc.M116.746438 (2017).

599 30 Tamura, K. *et al.* Molecular Mechanism by which Prominent Human Gut Bacteroidetes
600 Utilize Mixed-Linkage Beta-Glucans, Major Health-Promoting Cereal Polysaccharides. *Cell*
601 *reports* **21**, 417-430, doi:10.1016/j.celrep.2017.09.049 (2017).

602 31 Temple, M. J. *et al.* A Bacteroidetes locus dedicated to fungal 1,6-beta-glucan degradation:
603 Unique substrate conformation drives specificity of the key endo-1,6-beta-glucanase. *The*
604 *Journal of biological chemistry* **292**, 10639-10650, doi:10.1074/jbc.M117.787606 (2017).

605 32 Larsbrink, J. *et al.* A discrete genetic locus confers xyloglucan metabolism in select human
606 gut Bacteroidetes. *Nature* **506**, 498-502, doi:10.1038/nature12907 (2014).

607 33 Martens, E. C., Koropatkin, N. M., Smith, T. J. & Gordon, J. I. Complex glycan catabolism by
608 the human gut microbiota: the Bacteroidetes Sus-like paradigm. *The Journal of biological*
609 *chemistry* **284**, 24673-24677, doi:10.1074/jbc.R109.022848 (2009).

610 34 Reeves, A. R., Wang, G. R. & Salyers, A. A. Characterization of four outer membrane proteins
611 that play a role in utilization of starch by *Bacteroides thetaiotaomicron*. *Journal of*
612 *bacteriology* **179**, 643-649 (1997).

613 35 Thomas, F. *et al.* Characterization of the first alginolytic operons in a marine bacterium: from
614 their emergence in marine Flavobacteriia to their independent transfers to marine
615 Proteobacteria and human gut Bacteroides. *Environmental microbiology* **14**, 2379-2394,
616 doi:10.1111/j.1462-2920.2012.02751.x (2012).

617 36 Muchmore, E. A., Diaz, S. & Varki, A. A structural difference between the cell surfaces of
618 humans and the great apes. *American journal of physical anthropology* **107**, 187-198,
619 doi:10.1002/(sici)1096-8644(199810)107:2<187::aid-ajpa5>3.0.co;2-s (1998).

620 37 Park, K. H. *et al.* Structural and biochemical characterization of the broad substrate
621 specificity of *Bacteroides thetaiotaomicron* commensal sialidase. *Biochimica et biophysica*
622 *acta* **1834**, 1510-1519, doi:10.1016/j.bbapap.2013.04.028 (2013).

623 38 Almagro-Moreno, S. & Boyd, E. F. Insights into the evolution of sialic acid catabolism among
624 bacteria. *BMC evolutionary biology* **9**, 118, doi:10.1186/1471-2148-9-118 (2009).

625 39 Phansopa, C. *et al.* Characterization of a sialate-O-acetyltransferase (NanS) from the oral
626 pathogen *Tannerella forsythia* that enhances sialic acid release by NanH, its cognate
627 sialidase. *The Biochemical journal* **472**, 157-167, doi:10.1042/bj20150388 (2015).

628 40 Garbe, J. *et al.* EndoE from *Enterococcus faecalis* hydrolyzes the glycans of the biofilm
629 inhibiting protein lactoferrin and mediates growth. *PloS one* **9**, e91035,
630 doi:10.1371/journal.pone.0091035 (2014).

631 41 Waddling, C. A., Plummer, T. H., Jr., Tarentino, A. L. & Van Roey, P. Structural basis for the
632 substrate specificity of endo-beta-N-acetylglucosaminidase F(3). *Biochemistry* **39**, 7878-7885
633 (2000).

634 42 Green, E. D., Adelt, G., Baenziger, J. U., Wilson, S. & Van Halbeek, H. The asparagine-linked
635 oligosaccharides on bovine fetuin. Structural analysis of N-glycanase-released
636 oligosaccharides by 500-megahertz ¹H NMR spectroscopy. *The Journal of biological*
637 *chemistry* **263**, 18253-18268 (1988).

638 43 Tailford, L. E. *et al.* Mannose foraging by *Bacteroides thetaiotaomicron*: structure and
639 specificity of the beta-mannosidase, BtMan2A. *The Journal of biological chemistry* **282**,
640 11291-11299, doi:10.1074/jbc.M610964200 (2007).

641 44 Pluvinage, B. *et al.* Inhibition of the pneumococcal virulence factor StrH and molecular
642 insights into N-glycan recognition and hydrolysis. *Structure (London, England : 1993)* **19**,
643 1603-1614, doi:10.1016/j.str.2011.08.011 (2011).

644 45 Liu, T. *et al.* Structural determinants of an insect beta-N-Acetyl-D-hexosaminidase
645 specialized as a chitinolytic enzyme. *The Journal of biological chemistry* **286**, 4049-4058,
646 doi:10.1074/jbc.M110.184796 (2011).

647 46 Theodoratou, E. *et al.* Glycosylation of plasma IgG in colorectal cancer prognosis. *Scientific*
648 *reports* **6**, 28098, doi:10.1038/srep28098 (2016).

649 47 Martens, E. C., Chiang, H. C. & Gordon, J. I. Mucosal glycan foraging enhances fitness and
650 transmission of a saccharolytic human gut bacterial symbiont. *Cell host & microbe* **4**, 447-
651 457, doi:10.1016/j.chom.2008.09.007 (2008).

652 48 Martens, E. C., Roth, R., Heuser, J. E. & Gordon, J. I. Coordinate regulation of glycan
653 degradation and polysaccharide capsule biosynthesis by a prominent human gut symbiont.
654 *The Journal of biological chemistry* **284**, 18445-18457, doi:10.1074/jbc.M109.008094 (2009).

655 49 Kubinak, J. L. *et al.* MyD88 signaling in T cells directs IgA-mediated control of the microbiota
656 to promote health. *Cell host & microbe* **17**, 153-163, doi:10.1016/j.chom.2014.12.009
657 (2015).

658 50 Lawrence, R. M. & Pane, C. A. Human breast milk: current concepts of immunology and
659 infectious diseases. *Current problems in pediatric and adolescent health care* **37**, 7-36,
660 doi:10.1016/j.cppeds.2006.10.002 (2007).

661 51 Charnock, S. J. *et al.* Key residues in subsite F play a critical role in the activity of
662 *Pseudomonas fluorescens* subspecies cellulosa xylanase A against xylooligosaccharides but
663 not against highly polymeric substrates such as xylan. *The Journal of biological chemistry*
664 **272**, 2942-2951 (1997).

665 52 Gasteiger E., H. C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A. . Protein
666 Identification and Analysis Tools on the ExPASy Server. *The Proteomics Protocols Handbook.*,
667 571-607.

668 53 Kabsch, W. XDS. *Acta crystallographica. Section D, Biological crystallography* **66**, 125-132,
669 doi:10.1107/s0907444909047337 (2010).

670 54 Evans, P. Scaling and assessment of data quality. *Acta crystallographica. Section D, Biological*
671 *crystallography* **62**, 72-82, doi:10.1107/s0907444905036693 (2006).

672 55 Vonrhein, C., Blanc, E., Roversi, P. & Bricogne, G. Automated structure solution with
673 autoSHARP. *Methods in molecular biology (Clifton, N.J.)* **364**, 215-230, doi:10.1385/1-59745-
674 266-1:215 (2007).

675 56 Sheldrick, G. M. Experimental phasing with SHELXC/D/E: combining chain tracing with
676 density modification. *Acta crystallographica. Section D, Biological crystallography* **66**, 479-
677 485, doi:10.1107/s0907444909038360 (2010).

678 57 Cowtan, K. Recent developments in classical density modification. *Acta crystallographica.*
679 *Section D, Biological crystallography* **66**, 470-478, doi:10.1107/s090744490903947x (2010).

680 58 Cowtan, K. The Buccaneer software for automated model building. 1. Tracing protein chains.
681 *Acta crystallographica. Section D, Biological crystallography* **62**, 1002-1011,
682 doi:10.1107/s0907444906022116 (2006).

683 59 Murshudov, G. N. *et al.* REFMAC5 for the refinement of macromolecular crystal structures.
684 *Acta crystallographica. Section D, Biological crystallography* **67**, 355-367,
685 doi:10.1107/s0907444911001314 (2011).

686 60 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta*
687 *crystallographica. Section D, Biological crystallography* **66**, 486-501,
688 doi:10.1107/s0907444910007493 (2010).

689 61 Keegan, R. M. & Winn, M. D. Automated search-model discovery and preparation for
690 structure solution by molecular replacement. *Acta crystallographica. Section D, Biological*
691 *crystallography* **63**, 447-457, doi:10.1107/s0907444907002661 (2007).

692 62 Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. *Acta crystallographica.*
693 *Section D, Biological crystallography* **66**, 22-25, doi:10.1107/s0907444909042589 (2010).

694 63 McCoy, A. J. *et al.* Phaser crystallographic software. *Journal of applied crystallography* **40**,
695 658-674, doi:10.1107/s0021889807021206 (2007).

696 64 Chen, V. B. *et al.* MolProbity: all-atom structure validation for macromolecular
697 crystallography. *Acta crystallographica. Section D, Biological crystallography* **66**, 12-21,
698 doi:10.1107/s0907444909042073 (2010).

699 65 The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. .

700 66 The CCP4 suite: programs for protein crystallography. *Acta crystallographica. Section D,*
701 *Biological crystallography* **50**, 760-763, doi:10.1107/s0907444994003112 (1994).

702 67 Hehemann, J. H., Kelly, A. G., Pudlo, N. A., Martens, E. C. & Boraston, A. B. Bacteria of the
703 human gut microbiome catabolize red seaweed glycans with carbohydrate-active enzyme
704 updates from extrinsic microbes. *Proceedings of the National Academy of Sciences of the*
705 *United States of America* **109**, 19786-19791, doi:10.1073/pnas.1211002109 (2012).

706 68 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nature methods* **9**,
707 357-359, doi:10.1038/nmeth.1923 (2012).

708 69 Zerbino, D. R. *et al.* Ensembl 2018. *Nucleic acids research* **46**, D754-d761,
709 doi:10.1093/nar/gkx1098 (2018).

710 70 R: A language and environment for statistical computing. (2013).

711 71 Zhang, Z., Xie, J., Zhang, F. & Linhardt, R. J. Thin-layer chromatography for the analysis of
712 glycosaminoglycan oligosaccharides. *Analytical biochemistry* **371**, 118-120,
713 doi:10.1016/j.ab.2007.07.003 (2007).

714 72 Ceroni, A. *et al.* GlycoWorkbench: a tool for the computer-assisted annotation of mass
715 spectra of glycans. *Journal of proteome research* **7**, 1650-1659, doi:10.1021/pr7008252
716 (2008).

- 73 Juncker, A. S. *et al.* Prediction of lipoprotein signal peptides in Gram-negative bacteria. *Protein science : a publication of the Protein Society* **12**, 1652-1662, doi:10.1110/ps.0303703 (2003).
- 74 Sievers, F. *et al.* Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Molecular systems biology* **7**, 539, doi:10.1038/msb.2011.75 (2011).
- 75 Markowitz, V. M. *et al.* IMG: the Integrated Microbial Genomes database and comparative analysis system. *Nucleic acids research* **40**, D115-122, doi:10.1093/nar/gkr1044 (2012).
- 76 Lombard, V., Golaconda Ramulu, H., Drula, E., Coutinho, P. M. & Henrissat, B. The carbohydrate-active enzymes database (CAZy) in 2013. *Nucleic acids research* **42**, D490-495, doi:10.1093/nar/gkt1178 (2014).
- 77 Holm, L. & Laakso, L. M. Dali server update. *Nucleic acids research* **44**, W351-355, doi:10.1093/nar/gkw357 (2016).
- 78 *Protein structure comparison service PDBeFold at European Bioinformatics Institute.*
- 79 Dereeper, A., Audic, S., Claverie, J. M. & Blanc, G. BLAST-EXPLORER helps you building datasets for phylogenetic analysis. *BMC evolutionary biology* **10**, 8, doi:10.1186/1471-2148-10-8 (2010).
- 80 Dereeper, A. *et al.* Phylogeny.fr: robust phylogenetic analysis for the non-specialist. *Nucleic acids research* **36**, W465-469, doi:10.1093/nar/gkn180 (2008).
- 81 El-Gebali, S. *et al.* The Pfam protein families database in 2019. *Nucleic acids research*, doi:10.1093/nar/gky995 (2018).
- 82 Letunic, I. & Bork, P. 20 years of the SMART protein domain annotation resource. *Nucleic acids research* **46**, D493-d496, doi:10.1093/nar/gkx922 (2018).
- 83 Letunic, I., Doerks, T. & Bork, P. SMART: recent updates, new developments and status in 2015. *Nucleic acids research* **43**, D257-260, doi:10.1093/nar/gku949 (2015).

Acknowledgments

We thank Carl Morland (Newcastle University, UK) for his expert technical assistance, Fiona Cuskin (Newcastle University, UK) and Louise Royle (Ludger Ltd, UK) for insightful conversations about the data. We would like to thank Diamond Light Source (Oxfordshire, UK) for beamtime (proposal mx13587 and mx18598) and the staff of beamline I03 and 104-1 for assistance with crystal testing and data collection. We thank John Casement (Bioinformatics Support Unit, Newcastle University, UK) for analysing the raw RNAseq data. We thank Justin Sonnenberg (Stanford, USA) for the Δ BT0455 *Bt* strain, Rick Lewis (Newcastle University, UK) for his guidance and advice in looking for structural homologues and Robert Hirt for his advice on phylogenetics. The work was funded by BBSRC/Innovate UK IB catalyst award 'Glycoenzymes for Bioindustries' (BB/M029018/1).

Author contributions

J.B., A.S.L. and L.I.C carried out enzyme kinetics. J.B., P.A.U., A.S.L., O.R. and L.I.C. carried out enzymes assays. J.H. made substrates. J.B. and L.I.C. carried out *Bacteroides* growths. L.I.C carried out the whole cell assays. P.A.U. and O.R. carried out the LC-MS. P.A.U. and L.I.C. analysed the LC-MS data. J.B. and L.I.C. purified proteins and set up crystal trays. A.B. harvested crystals and collected data. A.B. and N.P. solved crystal structures. J.B., D.N. and L.I.C. produced *Bacteroides* gene deletion strains. L.I.C. carried out the bioinformatic analysis. L.I.C., D.N.B., P.A.U., J.B., A.S.L., D.I.R.S. and E.C.M designed experiments. L.I.C., E.C.L and D.N.B wrote the manuscript.

Competing interests

The authors declare no competing interests

Correspondence and requests for materials

Should be addressed to D.N.B or L.I.C.

Figure 1 | Complex N-glycans as a nutrient source in *Bacteroides* species a, Structure of a biantennary complex N-glycan (CNG) with other possible decorations and variations. The linkage is indicated by the key, however the sialic acid sugars can be attached through α 2,3 or 2,6 linkages to the galactose and also to the antennary GlcNAc. Biantennary CNG have both antennae linked through β 1,2 bonds and additional antenna have either a β 1,4-linkage (on the α 1,3 arm) or a β 1,6-linkage (on the α 1,6 arm) to produce tri- and tetra-antennary CNG, respectively. Common modifications to this core model are shown in dotted circles. **b**, Growth on native α ₁AGp of different *Bacteroides* spp. - *B. thetaiotaomicron* (*Bt*, black), *B. xylanisolvens* (*Bx*, dark blue), *B. ovatus* (*Bo*, red), *B. vulgatus* (*Bv*, dark green), *B. finegoldii* (*Bfine*, pink), *B. massiliensis* (*Bm*, magenta), *B. fragilis* (*Bf*, light green), *B. caccae* (*Bc*, light blue) and *B. cellulolyticus* (*Bcell*, orange). Growth curves were carried out at least twice for each species. **c**, Growth of *B. thetaiotaomicron* on glucose (5 mg/ml), α ₁AGp and deglycosylated α ₁AGp (both 20mg/ml) as the sole carbon source. **d**, Supernatant samples were taken at the start, 10 hour and 19 hour time points from the growth of *Bt* on α ₁AGp show in panel c and were analysed by SDS-PAGE. Fully glycosylated α ₁AGp is shown at T0 and fully deglycosylated α ₁AGp is the bottom 23.5 kDa protein band in the 10 h and 19 h time point lanes. **e**, TLC of the cell free spent media at the 10 h and 19 h time points to analyse glycans present. The top band is sialic acid (white arrow and “SA”) and two other faint glycan bands are indicated to (*). The results are representative of at least three independent replicates. Full versions of the gels and TLCs can be found in Supplementary Figure 1 and 23.

Figure 2 | Genes upregulated in *Bt* genes during growth on CNG a, A schematic of the 6 CAZyme-containing loci upregulated in *Bt* during growth on α ₁AGp. TM: transmembrane protein; pSGBP: putative surface glycan binding protein. **b**, A model of the degradation of CNGs by *Bt*. BT1625^{GH29} is placed in the periplasm but could in fact be facing the outside of the cell. The degradation of the common core tetrasaccharide likely occurs through the

activity of previously characterised enzymes located in the periplasm and cytoplasm (Supplementary Table 2, Supplemental Results and Discussion).

Figure 3 | The degradation of biantennary CNG by recombinant enzymes from *Bt* a, α_1 AGp digested with BT1044^{GH18} endo-GlcNAc'ase only and **b**, then in combination with BT0455^{GH33} sialidase, and **c**, then also BT0461^{GH2} β -galactosidase. **d-f**, Each of the assays shown in **a-c** were stopped after a 24 h incubation using heat denaturation and BT1035^{GH163} then added. The time shown for the different chromatograms varies between panels to provide clarity of the main peaks. The glycan products were labelled with procainamide and analysed by LC-FLD-ESI-MS (see Materials and Methods). The most abundant glycan products are annotated on the chromatograms and the minor products are shown in the key at the bottom. The same glycan species detected in multiple peaks is likely due to different linkages and glycosylation on different arms, which cannot be determined by the analytical methods employed. Neu5Ac and Neu5Gc are pink and light blue, respectively. The linkages they are attached through could not be determined using the techniques employed here and also likely vary between glycans and glycoproteins. The results are representative of at least three independent replicates. A sugar key is included in Figure 1.

Figure 4 | The activity of BT1044^{GH18} on immunoglobulin substrates and structural of the enzyme Activity of BT1044^{GH18} against **a**, human serum IgG **b**, human serum IgA and **c**, human colostrum IgA is shown in the presence of BT0455^{GH33} sialidase. The products with a β 1,4 bisecting GlcNAc are indicated to by a white asterisk. The results are representative of at least three independent replicates. **d**, Cartoon depiction of the predicted orientation of BT1044^{GH18} on the cell surface of *Bt* showing the attachment to the cell surface through a lipid anchor. Loops 1-7 on the surface of the enzyme with the active site are coloured yellow, green, orange, blue, magenta, purple and dark green, respectively. **e**, The surface of the BT1044^{GH18} crystal structure is shown again with the same loop colouring and the two catalytic residues are in red. For comparison, the previously published crystal structure of

the CNG-active enzyme EndoF3 (1EOM) from *Elizabethkingia meningoseptica* is shown (cyan). The conserved residues from the DxxDxDxE motif have been coloured orange and the approximate +1 (GlcNAc) and +1' (fucose) subsites are indicated to by white and red dashed lines, respectively. BT1044^{GH18} has more of a groove (white dashed box) in the equivalent section. The area where a bisecting GlcNAc would be predicted to sit is indicated to by an asterisk. This space is occupied in Endo F3, whereas in BT1044^{GH18} there is more space to accommodate this sugar, reflecting their respective activities (see Supplementary Fig. 21 for more details). The results are representative of at least three independent replicates.

Figure 5 | GH20 activity on α_1 AGp Activity was assessed for **a**, BT0506^{GH20}, **b**, BT0456^{GH20}, **c**, BT0460^{GH20} and **d**, BT0459^{GH20}. Procainamide labelled products were analysed as described previously for other assays and the samples were pre-digested with BT0455^{GH33}, BT1044^{GH18} and BT0461^{GH2}. The results are representative of at least three independent replicates.

Figure 6 | Crystal structure of BT0459^{GH20} **a**, A close up of the active site of BT0459^{GH20} with the residues forming the -1 subsite shown as sticks and a GlcNAc (blue) product in the active site. **b**, A close up of the active site of BT0459^{GH20} overlaid with a CNG structure (from 2YLA). Mannose and GlcNAc are green and blue, respectively, with the antennary GlcNAc in the active site. The α 1,3 mannose arm is in the +1 position and the core mannose and GlcNAc occupy the +2 and +3 subsites, respectively. A clash can be seen between the Y433 and the bisecting GlcNAc in the +2' position. The active sites of the *S. pneumoniae* **c**, SpGH20A and **d**, SpGH20B, and **e**, a GH20 active on chitooligosaccharides from *O. furnacalis*. The inhibitor in **e** is TMG-chitotriomycin (TMG and GlcNAcs shown in cyan and dark blue, respectively). Catalytic residues are shown in red and those residues interacting with sugars in the positive subsites are in orange. **f**, The full length structure of BT0459^{GH20} and **g**, the *S. marcescens* GH20 (1C7S). The order of the modules are shown as coloured

855 bars. **h**, The C-terminal F5/F8 type C domain of BT0459^{GH20} is shown (BT0459^{F5/F8TypeC}, left)
856 and aromatic residues on the potential glycan binding surface are shown as sticks. A
857 structural homologue of BT0459^{F5/F8TypeC} is shown for comparison (right) and is a CBM32
858 from a *C. perfringens* GH84 (*CpCBM32*). This has a trisaccharide ligand of fucose,
859 galactose and GlcNAc (red, yellow and blue, respectively) bound and the aromatic residues
860 involved in binding are shown as sticks. The core folds between BT0459^{F5/F8TypeC} and
861 *CpCBM32* are very similar but the potential glycan binding surfaces vary greatly (see
862 Supplementary Fig. 12 for further structural homologues).

a **b**